Clinical trial
Dose Optimization Study of Idelalisib in Follicular Lymphoma
This study will optimize the safety and efficacy of chronic administration of idelalisib in participants with follicular lymphoma (FL) and evaluate the overall safety profile of idelalisib and the overall response rate (ORR) by Week 24.
| Category | Value |
|---|---|
| Date last updated at source | 2017-05-09 |
| Study type(s) | Interventional |
| Expected enrolment | 240 |
| Study start date | 2016-01-14 |
| Estimated primary completion date | 2021-08-01 |